Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their remission rates vary. New therapies have been introduced for the treatment of EoE, expanding available therapeutic options. These agents include Takeda’s Eohilia (budesonide oral suspension), which received FDA approval in 2024, and Sanofi / Regeneron’s Dupixent (dupilumab), which received FDA approval in 2022 and EC approval in 2023. Additionally, the EC approved Dr. Falk’s Jorveza (budesonide orodispersible tablets) in 2018. The treatment landscape for EoE is evolving; several early- and late-phase agents (e.g., cendakimab, tezepelumab, APT-1011) aim to target key inflammatory pathways implicated in EoE. Understanding prescriber perceptions of the available options and the drivers behind prescribers’ clinical decision-making in EoE can help drug developers identify levers for new product positioning and differentiation.

Questions answered

• How do current therapies such as Dupixent, Eohilia, and Jorveza perform on key treatment drivers and goals for EoE?
• Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• Where do surveyed gastroenterologists perceive the largest gaps in the treatment of EoE?
• What trade-offs across different clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new EoE drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 34 European gastroenterologist, fielded in February 2026

Key companies: Sanofi / Regeneron Pharmaceuticals, Takeda Pharmaceuticals, Dr. Falk Pharma

Key drugs: Dupixent, Eohilia, Jorveza

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Key feature

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.